1

#### 1 **TITLE: Predicting thoracic aortic dissection in a diverse biobank using a**  2 **polygenic risk score**

- 3
- 4 **Authors:** John DePaolo, MD, PhD,<sup>1</sup>\* Siavash Zamirpour, MS,<sup>2</sup>\* Sarah Abramowitz,
- 5 BA,<sup>1</sup> Gina Biagetti, MD,<sup>3</sup> Renae Judy, MS,<sup>1</sup> Cameron Beeche, BS,<sup>4,5</sup> Jeffrey Duda<sup>6</sup>,
- 6 James Gee $<sup>6</sup>$ , Walter R. Witschey, PhD, $<sup>6</sup>$  Julio A. Chirinos, MD, PhD, $<sup>5</sup>$  Nicholas J. Goel,</sup></sup></sup>
- 7 MD,<sup>7</sup> Nimesh Desai, MD, PhD,<sup>7</sup> Wilson Y. Szeto, MD,<sup>7</sup> Dongchuan Guo, PhD,<sup>8</sup> Dianna
- 8 M. Milewicz, MD, PhD, $^8$  Michael G. Levin, MD, $^{5,9}$  James P. Pirruccello, MD<sup>2,10,11#</sup> Scott
- 9 M. Damrauer, MD,  $^{3,9,12,13\#}$
- 10

## 11 **Affiliations:**

- 12 <sup>1</sup> Department of Surgery, Perelman School of Medicine, University of Pennsylvania, 13 Philadelphia, PA, USA.
- <sup>2</sup> Institute for Human Genetics, University of California San Francisco, San Francisco,
- 15 CA, USA.
- <sup>3</sup> Division of Vascular Surgery and Endovascular Therapy, Department of Surgery,
- 17 Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
- 18 <sup>4</sup> Department of Bioengineering, University of Pennsylvania, PA, USA.
- <sup>5</sup> Division of Cardiovascular Medicine, Department of Medicine, Perelman School of
- 20 Medicine, University of Pennsylvania, PA, USA.
- <sup>6</sup> Department of Radiology, Perelman School of Medicine, University of Pennsylvania, 22 PA, USA.
- <sup>7</sup> Division of Cardiovascular Surgery, Department of Surgery, Perelman School of
- 24 Medicine, University of Pennsylvania, Philadelphia, PA, USA.
- <sup>8</sup>25 Division of Medical Genetics, Department of Internal Medicine, McGovern Medical
- 26 School, University of Texas Health Science Center at Houston, Houston, TX, USA.
- <sup>9</sup> Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA.
- $10^{10}$  Division of Cardiology, University of California San Francisco, San Francisco, CA, 29 USA.
- 30 <sup>11</sup> Bakar Computation Health Sciences Institute, University of California San Francisco, 31 San Francisco, CA, USA.
- 32 <sup>12</sup> Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, 33 PA, USA.
- <sup>13</sup> Department of Genetics, Perelman School of Medicine, University of Pennsylvania,
- 35 Philadelphia, PA, USA.
- 36
- 37
- 38 \* These authors contributed equally to this work
- $39$   $*$  These authors jointly supervised the work
- 40
- 41
- 42 **Brief Title:** Polygenic scoring for dissection risk
- 43 **Word count** : 4305
- 44 **References** : 41
- 45 **Tables** : 1
- 46 **Figures** : 4

#### **Address for correspondence:**

- Scott Damrauer, MD
- Division of Vascular Surgery and Endovascular Therapy
- Hospital of the University of Pennsylvania
- 3400 Civic Center Drive, 14th Floor South Perelman Center
- Philadelphia, PA 19104
- Office: 215-615-1698
- damrauer@upenn.edu

#### **Abstract**

**Background**: Thoracic aortic dissection is a life-threatening condition that often occurs in the presence of aortic dilation. Despite a known association between ascending aortic diameter (AscAoD) and dissection risk, predicting dissection risk remains challenging. **Objectives**: Determine whether common variant genetics can be used to improve identification of individuals most at risk for dissection. **Methods**: A genome wide association study (GWAS)-by-subtraction was performed to characterize the diameter-independent genetics of thoracic aortic dissection by subtracting a GWAS of aortic diameter (AoD) from a GWAS of thoracic aortic aneurysm and dissection (TAAD). A polygenic risk score (PRS) was calculated using the PRS-Continuous Shrinkage statistical package and evaluated for its ability to predict aortic dissection. The primary analytic cohort was Penn Medicine Biobank (PMBB) which comprises volunteers consenting to linkage of health records with biospecimens, including DNA which has undergone genome-wide genotyping; additional analyses were performed in the National Institutes of Health All of Us (AoU) cohort. **Results**: We identified 43 significant genetic risk loci in our GWAS-by-subtraction and derived a "Dissection-PRS." In the PMBB, the Dissection-PRS associated with an increased risk of prevalent dissection (odds ratio [OR]=2.13 per 1 standard deviation [sd] increase in Dissection-PRS, 95% confidence interval [CI] 1.91 to 2.39, *P*<0.001), These results were consistent when excluding individuals with pathogenic or likely pathogenic variants in established aortopathy genes. When adjusting for clinical risk factors including ascending aortic diameter, the association of the Dissection-PRS with prevalent dissection attenuated but remained significant (OR=1.62 per 1 sd increase in

- PRS, 95% CI 1.36 to 1.94, *P*<0.001). The addition of the PRS to a model containing
- age, sex, clinical risk factors, and ascending aortic diameter substantially improved
- model discrimination (base model area under the receiver operator characteristic curve
- [AUROC]=0.676, 95% CI 0.651 to 0.702; with addition of PRS AUROC=0.723, 95% CI
- 0.702 to 0.744). Analysis in AoU demonstrated similar findings.
- **Conclusions:** A common-variant PRS can predict aortic dissection in a diverse
- population.

## **Abbreviations**

- **AoD** Aortic diameter
- **AscAoD** Ascending aortic diameter
- **AUROC** Area under the receiver operator characteristic curve
- **CI** Confidence interval
- **CT** Computed tomography
- **CRF** Clinical Risk Factors
- **DesAoD** Descending aortic diameter
- **PRS** Polygenic risk score
- **ROC** Receiver operator characteristic curve
- **SEM** Structural equation modeling
- **TAAD** Thoracic aortic aneurysm and dissection
- **TTE** Transthoracic echocardiography
- 

#### 

#### **Main Text**

#### **Introduction**

Thoracic aortic dissection is characterized by tearing of the intimal layer of the thoracic aorta, more commonly in the ascending portion (Stanford Type A dissection), leading to formation of a false lumen resulting in antegrade and/or retrograde 105 malperfusion.<sup>1</sup> Dissection has an incidence rate of approximately 3-10 per 100,000 106 individuals annually,  $2-5$  and although rare, acute dissection can have devastating health consequences with 30-day mortality rates ranging from 17% to more than 50% when 108 considering out-of-hospital deaths. $6-11$  Currently, individuals with dilated or aneurysmal thoracic aortas are treated with aggressive blood pressure management and serial 110 imaging with elective surgical repair at ascending thoracic aortic diameters (AscAoD)  $\geq$  $5-5.5$  cm.<sup>12</sup> However, it has become increasingly evident by the prevalence of dissection among individuals with AscAoD < 5.5 cm that this size cutoff alone is insufficient to 113 guide clinical decision making.<sup>13</sup> Dissection, along with ascending and descending thoracic aortic aneurysms, are included in the group of related conditions referred to as thoracic aortic aneurysm and dissection (TAAD). Rare pathogenic (P) or likely pathogenic (LP) variants in several Mendelian aortopathy genes associated with hereditary TAAD (HTAAD) are causally 118 linked to familial and/or syndromic disease.<sup>14,15</sup> Notably, due to overwhelming genetic

risk, the size threshold for surgical intervention to prevent dissection is lower among

individuals with P/LP rare variants in a subset of aortopathy genes associated with

121 familial or syndromic disease.<sup>12</sup> Despite TAAD being historically thought of as a

Mendelian disease, approximately 80% of cases of TAAD occur among individuals



#### **Methods**

*Study Population*

PMBB

The Penn Medicine BioBank is a genomic and precision medicine cohort 143 comprising participants who receive care in the Penn Medicine health system and who consent to linkage of electronic health records with biospecimens, including 43,731 with DNA which has undergone whole exome sequencing and 43,623 which has undergone





*Genome Wide Association Study*

GWAS-by-subtraction was performed using Genomic-Structural Equation 182 Modeling (SEM), as previously described.<sup>27</sup> Genomic-SEM is a flexible modeling framework that allows a user to create systems of equations to model relationships between the genetic components of observed traits and related latent traits. Because TAAD comprises both aortic aneurysm (i.e. large aortic diameter) and dissection, we posited that subtracting the genetic contribution of aortic size from TAAD would isolate the genetics of aortic dissection. Using publicly available summary statistics from 188 GWAS of TAAD, ascending aortic diameter (AscAoD),  $17$  and descending aortic 189 diameter (DesAoD)<sup>17</sup> (summary information in **Supplemental Table 1**) we employed the genomic-SEM framework to perform GWAS-by-subtraction based on a Cholesky



*Polygenic risk score creation* 

213 PRS-CSx-auto<sup>30</sup> was used to construct a PRS for each of the following traits: 1) 214 AscAoD from a GWAS performed among 38,694 UKB participants;<sup>17</sup> 2) TAAD from a GWAS among a diverse population of 461,669 MVP participants (8,626 cases, 453,043 216 disease-free controls);<sup>19</sup> 3) thoracic aortic dissection ("Dissection-PRS") using our GWAS-by-subtraction summary statistics described above. These are described further

#### in the **Supplemental Methods**.

To apply each PRS in the PMBB, individual participant scores were calculated 220 using pgsc calc, a pipeline developed by the PGS Catalog that computes individual 221 scores by combining imputed genotypes with PRS weights. As allele frequency differences across diverse populations can influence PRS distribution and limit accuracy, pgsc\_calc allows a genetic principal component (PC)-based method to normalize scores across populations by adjusting the mean and variance relative to the 225 1000 Genomes Project and Human Genomes Diversity Project (HGDP).<sup>32</sup> In this approach, a PC space is created using reference populations and a PRS is modeled as 227 a linear function of the PCs. Score residuals are calculated as the difference between the observed and predicted PRS, and then divided by the standard deviation of the residuals. This ensures that the adjusted PRS values have a mean of 0 when considering the influence of population diversity. To adjust for the variations in PRS range, the variance of the residuals is modeled as a function of the PCs, and then is used to normalize the residual PRS. The variance of the final PRS values distribution is therefore approximately 1 across all populations.

*Prediction model creation*



*Study population for PRS Analysis* 



*Genome-wide association study-by-subtraction*



Compared to individuals without a diagnosis of dissection (median PRS = 0.03, 95% CI = 0.01 to 0.04), individuals with a diagnosis of dissection had a significantly 304 higher median PRS (0.88, 95% CI 0.68 to 1.06, P=1.07x10<sup>-30</sup>) [Supplemental Figure



in AOU though with an attenuated effect in the AFR population, and is independent of

P/LP HTAAD gene variants.

*Effect of Dissection-PRS when adjusting for known risk factors* 

- To determine if the Dissection-PRS was independently associated with prevalent
- dissection independent of other risk factors, we performed multivariable logistic
- regression analysis adjusting for CRF including age, sex, height, weight, BMI, BSA,
- SBP, DBP, and HR. When we adjusted for these variables, the effect of the Dissection-
- PRS remained consistent (OR=2.29 per 1 sd increase in PRS, 95% CI 1.97 to 2.65,
- *P*<0.001) [**Figure 3**].

As AscAoD is the most critical clinical factor in determining when to offer surgical

337 intervention,  $12,13$  we repeated our multivariable logistic regression to also adjust for

AscAoD among 7,974 individuals with AscAoD measured by TTE (7,414) or CT (560)

[**Supplemental Table 4**]. When adjusting for AscAoD alone (OR=1.59 per 1 sd increase

in PRS, 95% CI 1.33 to 1.92, *P*<0.001), or AscAoD and CRF (OR=1.61 per 1 sd

increase in PRS, 95% CI 1.35 to 1.92, *P*<0.001), the effect estimate of the Dissection-

PRS was attenuated but remained statistically significant [**Figure 3**]. These results

suggest that the risk of dissection associated with the Dissection-PRS is completely

independent of CRFs and largely independent of measured AscAoD.

#### *PRS effect on predictive model calibration*

To determine if the Dissection-PRS could improve identification of individuals at increased risk of dissection, we integrated the Dissection-PRS in prediction models and compared model performance with and without the PRS. To determine the effect of the



group (**Supplemental Figures 14-16, Summary Tables 9-10**). These results lead us to conclude that the Dissection-PRS consistently enhances clinical model calibration.

*PRS effect on model discrimination*

The ability to determine patients most at risk of dissection, especially among individuals with ascending thoracic aortic dilation, remains elusive. To investigate whether the Dissection-PRS could meaningfully improve clinical prediction model discrimination between individuals with and without dissection, we tested whether its inclusion increased model area under receiver operator characteristic curve (AUROC). The Age + Sex model had an AUROC=0.572 (95% CI 0.547 to 0.597) [**Figure 4**]. The Age + Sex + CRF model had an AUROC=0.634 (95% CI 0.610 to 0.657), whereas the Age + Sex + CRF + Dissection-PRS had an AUROC=0.700 (95% CI 0.677 to 0.722). Similarly, the Age + Sex + CRF + AscAoD model had an AUROC=0.676 (95% CI 0.651 to 0.702), whereas the Age + Sex + CRF + AscAoD + Dissection-PRS model had an AUROC=0.723 (95% CI 0.702 to 0.744). To determine if the addition of the PRS meaningfully improved model discrimination, we once more employed cross-model Bayesian analysis of AUROC. The addition of the Dissection-PRS to the Age + Sex + CRF model (AUROC mean difference = 0.066, 95% credible interval 0.057 to 0.075;  $>95\%$  probability of a practical improvement in AUROC) and the Age + Sex + CRF + AscAoD (AUROC mean difference = 0.047, 95% credible interval 0.037 to 0.056;  $>95\%$ probability of a practical improvement in AUROC) [**Supplemental Figure 17, Supplemental Table 11**], demonstrated that the Dissection-PRS meaningfully improved model AUROC. These results were supported with frequentist analysis of differences in AUROC using the DeLong method (**Supplemental Table 12**). Models were once more



## **Discussion**

Identification of diameter-independent risk factors for dissection remains one of the key unresolved challenges in preventing premature deaths due to thoracic aortic

disease. In this study, we performed a GWAS-by-subtraction that identified 43 genetic loci associated with diameter-independent thoracic aortic disease, 20 of which were previously unreported. From our summary statistics, we created a PRS that strongly associated with dissection in the PMBB independent of clinical variables including AscAoD and validated our findings in AOU. We then demonstrated that inclusion of the Dissection-PRS in a clinical risk prediction model improves model calibration and discrimination across diverse populations.

The explanation for the improvement in the strength of association with prevalent and incident dissection provided by the Dissection-PRS, as compared to the TAAD-PRS or AscAoD-PRS, is likely partially explained by the identification of novel variants associated with dissection using the GWAS-by-subtraction methodology. However, some of the improvement is also likely due to the subtle statistical reweighting of known variants such that the weights are substantially changed and reflected in the overall observed PRS effect. For example, the effect estimate of the *CDH13* risk locus in the TAAD GWAS was -0.12 while the effect estimate in our GWAS-by-subtraction was - 0.14. The enhancement in PRS performance raises the prospect of a true dissection GWAS, rather than the present one inferred through latent values, and whether a PRS from such a GWAS would exceed what we have shown in this present study. In future work, it will also be interesting to attempt to de-convolve the Dissection-PRS into recognizable features (e.g., features of aortic geometry; properties of the aortic wall; etc.).

Determining which patients should receive prophylactic surgical intervention to prevent an acute dissection, and the timing of that intervention, represents an ongoing

challenge in cardiovascular medicine and surgery. While the standard AscAoD size 443 threshold for repair remains 5-5.5 cm, it is clear from retrospective data that this 444 threshold is insufficient to identify at-risk individuals.<sup>13</sup> Despite myriad attempts to 445 develop algorithms to better predict dissection risk,  $34-37$  there remains limited clinical implementation of risk factors other than AscAoD, rate of diameter growth, and family history. Genetic data is changing the way we interpret multi-factorial disease risk. Our results suggest that using common genetic risk factors aggregated in a PRS can contribute to improved assessment of dissection risk and may enhance patient selection for surgical intervention.

Importantly, the Dissection-PRS had a similar effect on dissection risk across diverse populations. This was true in incident analyses across both the primary and validation cohorts, as well as prevalent analyses in the primary cohort. We also observed robust prediction model discrimination improvement with the addition of the Dissection-PRS in both the EUR and AFR population groups. Extensive investigation 456 has been performed on the lack of portability of PRS across diverse populations.<sup>38,39</sup> The present multi-trait GWAS-by-subtraction is benefited by the diversity inherent in the previously published TAAD GWAS in the MVP and not penalized by subtracting out AoD using summary statistics from a GWAS largely performed in an EUR population. The use of multi-trait GWAS from more diverse parent GWAS data to derive equitable PRS may improve PRS portability as biobanks continue to work to overcome historical lack of diversity.

Determining if a prediction model that includes a PRS improves patient identification will require prospective investigation. For example, future studies may

benefit from incorporating a model that includes a PRS for thoracic aortic dissection among patients at risk of dissection to identify those patients who could be considered for expedited repair at a lower diameter threshold. One way to address this is to prospectively enroll individuals at high volume aortic centers with dilated ascending thoracic aortas to have genetic testing and PRS calculation, and integrating the individual PRS into a model to predict dissection risk. Subsequently, individuals would be followed over time to determine the utility of such a model. As thoracic aortic dissection is a relatively rare event, coordinated efforts across many different aortic centers may be better powered to demonstrate an effect.

*Limitations*

This study has several limitations. First, our GWAS-by-subtraction is not a true GWAS of dissection and should not be misconstrued as serving that purpose, although 477 it will be interesting to compare these findings with future thoracic dissection GWAS as they become available. Second, the PMBB is enriched for cases of dissection and the robust association of the Dissection-PRS with prevalent and incident dissection may be overestimated in this cohort. Third, dissection is a relatively rare event and therefore any understanding of the true predictive capacity of the Dissection-PRS would be best evaluated prospectively. Fourth, for the TTE data in the PMBB, each TTE was interpreted by a cardiologist in a clinical echocardiography lab, which is accredited by the Intersocietal Commission for the Accreditation of Echocardiography Labs and staffed by cardiologists who are board-certified in echocardiography. However, each TTE was not interpreted by the same cardiologist and small differences in measurement and interpretation may exist between studies. Additionally, although we used the largest



research program. We would also like to thank the Penn Medicine BioBank team and Regeneron Genetics Center for providing genetic variant data for analysis. The PMBB is approved under IRB protocol# 813913 and supported by Perelman School of Medicine at University of Pennsylvania, a gift from the Smilow family, and the National Center for Advancing Translational Sciences of the National Institutes of Health under CTSA award number UL1TR001878. The summary statistics for the TAAD GWAS performed in the MVP were obtained through dbGaP, accession number phs001672.v11.p1. The authors thank the MVP staff, researchers, and volunteers who have contributed to MVP, and especially participants who previously served their country in the military and now generously agreed to enroll in the study. (See https://www.research.va.gov/mvp/ for more details). This research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by the Veterans Administration (VA) MVP award #000. The All of Us Research Program is supported by the National Institutes of Health, Office of the Director: Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA #: AOD 16037; Federally Qualified Health Centers: HHSN 263201600085U; Data and Research Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176; Participant Technology Systems Center: 1 U24 OD023163; Communications and Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2 OD025276. We gratefully acknowledge *All of Us* participants for their contributions, without whom this research would not have been possible. We also thank

- the National Institutes of Health's *All of Us* Research Program for making available the participant data examined in this study.
- 

#### **Sources of Funding**

- J.D. is supported by the American Heart Association (23POST1011251). The
- views expressed in this article are those of the authors and do not necessarily reflect
- the position or policy of the Department of Veterans Affairs or the United States
- government. W.R.W. is supported by NIH R01 HL171709, P41 EB029460, and R01
- HL169378. D.M.M. and D.C.G. are supported by the NIH (R01HL109942), the John
- Ritter Foundation. M.G.L. received support from the Doris Duke Foundation (2023-
- 0224) and Department of Veterans Affairs Biomedical Research and Development

Award IK2-BX006551. J.P.P is supported by the NIH (K08HL159346).

### **Disclosures**

M.G.L. receives research support to his institution from MyOme outside of this work. S.M.D receives research support to his institution from RenalytixAI and in kind support from Novo Nordisk, both outside of this work. SMD is named as a co-inventor on a government-owned US Patent application related to the use of genetic risk prediction for venous thromboembolic disease filed by the US Department of Veterans Affairs in accordance with Federal regulatory requirements.

- **Supplemental Material**
- Supplement 1

- Supplemental table 1-2
- Supplement 2
- Supplemental Methods
- Supplemental Results
- Supplemental Authors
- Supplemental Tables 3-16
- Supplemental Figures 1-24

#### **References**

- 1. Gudbjartsson T, Ahlsson A, Geirsson A, Gunn J, Hjortdal V, Jeppsson A,
- Mennander A, Zindovic I, Olsson C. Acute type A aortic dissection a review.
- *Scandinavian Cardiovascular Journal*. 2020;54:1-13. doi:
- 10.1080/14017431.2019.1660401
- 2. DeMartino RR, Sen I, Huang Y, Bower TC, Oderich GS, Pochettino A, Greason
- K, Kalra M, Johnstone J, Shuja F, et al. Population-Based Assessment of the
- Incidence of Aortic Dissection, Intramural Hematoma, and Penetrating Ulcer, and
- Its Associated Mortality From 1995 to 2015. *Circ Cardiovasc Qual Outcomes*.
- 2018;11:e004689. doi: 10.1161/CIRCOUTCOMES.118.004689
- 3. Clouse WD, Hallett JW, Jr., Schaff HV, Spittell PC, Rowland CM, Ilstrup DM,
- Melton LJ, 3rd. Acute aortic dissection: population-based incidence compared
- with degenerative aortic aneurysm rupture. *Mayo Clin Proc*. 2004;79:176-180.

doi: 10.4065/79.2.176

- 4. Olsson C, Thelin S, Ståhle E, Ekbom A, Granath F. Thoracic aortic aneurysm
- and dissection: increasing prevalence and improved outcomes reported in a
- nationwide population-based study of more than 14,000 cases from 1987 to
- 2002. *Circulation*. 2006;114:2611-2618. doi: 10.1161/circulationaha.106.630400
- 5. Mody PS, Wang Y, Geirsson A, Kim N, Desai MM, Gupta A, Dodson JA,
- Krumholz HM. Trends in aortic dissection hospitalizations, interventions, and
- outcomes among medicare beneficiaries in the United States, 2000-2011. *Circ*
- *Cardiovasc Qual Outcomes*. 2014;7:920-928. doi:
- 10.1161/circoutcomes.114.001140



- Myrmel T, Larsen M, Harris Kevin M, Greason K, et al. Presentation, Diagnosis,
- and Outcomes of Acute Aortic Dissection. *Journal of the American College of*

*Cardiology*. 2015;66:350-358. doi: 10.1016/j.jacc.2015.05.029

- 7. McClure RS, Ouzounian M, Boodhwani M, El-Hamamsy I, Chu MWA, Pozeg Z,
- Dagenais F, Sikdar KC, Appoo JJ. Cause of Death Following Surgery for Acute
- Type A Dissection: Evidence from the Canadian Thoracic Aortic Collaborative.

*Aorta (Stamford)*. 2017;5:33-41. doi: 10.12945/j.aorta.2017.16.034

- 8. Verstraeten A, Luyckx I, Loeys B. Aetiology and management of hereditary
- aortopathy. *Nat Rev Cardiol*. 2017;14:197-208. doi: 10.1038/nrcardio.2016.211
- 9. Melvinsdottir IH, Lund SH, Agnarsson BA, Sigvaldason K, Gudbjartsson T,
- Geirsson A. The incidence and mortality of acute thoracic aortic dissection:
- results from a whole nation study. *Eur J Cardiothorac Surg*. 2016;50:1111-1117.
- doi: 10.1093/ejcts/ezw235
- 10. Howard DP, Banerjee A, Fairhead JF, Perkins J, Silver LE, Rothwell PM, Oxford
- Vascular S. Population-based study of incidence and outcome of acute aortic
- dissection and premorbid risk factor control: 10-year results from the Oxford
- Vascular Study. *Circulation*. 2013;127:2031-2037. doi:
- 10.1161/CIRCULATIONAHA.112.000483
- 11. Evangelista A, Isselbacher EM, Bossone E, Gleason TG, Eusanio MD, Sechtem
- U, Ehrlich MP, Trimarchi S, Braverman AC, Myrmel T, et al. Insights From the
- International Registry of Acute Aortic Dissection: A 20-Year Experience of

Collaborative Clinical Research. *Circulation*. 2018;137:1846-1860. doi:

- 10.1161/CIRCULATIONAHA.117.031264
- 12. Isselbacher EM, Preventza O, Hamilton Black J, 3rd, Augoustides JG, Beck AW,
- Bolen MA, Braverman AC, Bray BE, Brown-Zimmerman MM, Chen EP, et al.
- 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease:
- A Report of the American Heart Association/American College of Cardiology
- Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022;146:e334-
- e482. doi: 10.1161/CIR.0000000000001106
- 13. Pape LA, Tsai TT, Isselbacher EM, Oh JK, O'Gara P T, Evangelista A, Fattori R,
- Meinhardt G, Trimarchi S, Bossone E, et al. Aortic diameter >or = 5.5 cm is not a
- good predictor of type A aortic dissection: observations from the International
- Registry of Acute Aortic Dissection (IRAD). *Circulation*. 2007;116:1120-1127. doi:
- 10.1161/circulationaha.107.702720
- 14. Wolford BN, Hornsby WE, Guo D, Zhou W, Lin M, Farhat L, McNamara J,
- Driscoll A, Wu X, Schmidt EM, et al. Clinical Implications of Identifying
- Pathogenic Variants in Individuals With Thoracic Aortic Dissection. *Circ Genom*
- *Precis Med*. 2019;12:e002476. doi: 10.1161/CIRCGEN.118.002476
- 15. Renard M, Francis C, Ghosh R, Scott AF, Witmer PD, Ades LC, Andelfinger GU,
- Arnaud P, Boileau C, Callewaert BL, et al. Clinical Validity of Genes for Heritable
- Thoracic Aortic Aneurysm and Dissection. *J Am Coll Cardiol*. 2018;72:605-615.
- doi: 10.1016/j.jacc.2018.04.089
- 16. Pinard A, Jones GT, Milewicz DM. Genetics of Thoracic and Abdominal Aortic
- Diseases. *Circ Res*. 2019;124:588-606. doi: 10.1161/CIRCRESAHA.118.312436



Dissection. *Genes (Basel)*. 2022;13. doi: 10.3390/genes13101814

- 23. Takada M, Yamagishi K, Tamakoshi A, Iso H, Group JS. Body Mass Index and
- Mortality From Aortic Aneurysm and Dissection. *J Atheroscler Thromb*.
- 2021;28:338-348. doi: 10.5551/jat.57232
- 24. Zafar MA, Li Y, Rizzo JA, Charilaou P, Saeyeldin A, Velasquez CA, Mansour AM,
- Bin Mahmood SU, Ma WG, Brownstein AJ, et al. Height alone, rather than body
- surface area, suffices for risk estimation in ascending aortic aneurysm. *J Thorac*
- *Cardiovasc Surg*. 2018;155:1938-1950. doi: 10.1016/j.jtcvs.2017.10.140
- 25. Pirruccello JP, Lin H, Khurshid S, Nekoui M, Weng LC, Vasan RS, Isselbacher
- EM, Benjamin EJ, Lubitz SA, Lindsay ME, Ellinor PT. Development of a
- Prediction Model for Ascending Aortic Diameter Among Asymptomatic
- Individuals. *JAMA*. 2022;328:1935-1944. doi: 10.1001/jama.2022.19701
- 26. Beeche C, Dib MJ, Zhao B, Azzo JD, Maynard H, Duda J, Gee J, Salman O,
- Penn Medicine B, Witschey WR, Chirinos JA. Three-dimensional aortic
- geometry: clinical correlates, prognostic value and genetic architecture. *bioRxiv*.
- 2024. doi: 10.1101/2024.05.09.593413
- 27. Demange PA, Malanchini M, Mallard TT, Biroli P, Cox SR, Grotzinger AD,
- Tucker-Drob EM, Abdellaoui A, Arseneault L, van Bergen E, et al. Investigating
- the genetic architecture of noncognitive skills using GWAS-by-subtraction. *Nat*
- *Genet*. 2021;53:35-44. doi: 10.1038/s41588-020-00754-2
- 28. St Pourcain B, Eaves LJ, Ring SM, Fisher SE, Medland S, Evans DM, Davey
- Smith G. Developmental Changes Within the Genetic Architecture of Social
- Communication Behavior: A Multivariate Study of Genetic Variance in Unrelated

- Individuals. *Biol Psychiatry*. 2018;83:598-606. doi:
- 10.1016/j.biopsych.2017.09.020
- 29. Grotzinger AD, Rhemtulla M, de Vlaming R, Ritchie SJ, Mallard TT, Hill WD, Ip
- HF, Marioni RE, McIntosh AM, Deary IJ, et al. Genomic structural equation
- modelling provides insights into the multivariate genetic architecture of complex
- traits. *Nat Hum Behav*. 2019;3:513-525. doi: 10.1038/s41562-019-0566-x
- 30. Ruan Y, Lin YF, Feng YA, Chen CY, Lam M, Guo Z, Stanley Global Asia I, He L,
- Sawa A, Martin AR, et al. Improving polygenic prediction in ancestrally diverse
- populations. *Nat Genet*. 2022;54:573-580. doi: 10.1038/s41588-022-01054-7
- 31. Lambert SA, Gil L, Jupp S, Ritchie SC, Xu Y, Buniello A, McMahon A, Abraham
- G, Chapman M, Parkinson H, et al. The Polygenic Score Catalog as an open
- database for reproducibility and systematic evaluation. *Nature Genetics*.
- 2021;53:420-425. doi: 10.1038/s41588-021-00783-5
- 32. Fairley S, Lowy-Gallego E, Perry E, Flicek P. The International Genome Sample
- Resource (IGSR) collection of open human genomic variation resources. *Nucleic*
- *Acids Res*. 2020;48:D941-D947. doi: 10.1093/nar/gkz836
- 33. Therneau TM, Grambsch PM. The Cox Model. In: Therneau TM, Grambsch PM,
- eds. *Modeling Survival Data: Extending the Cox Model*. New York, NY: Springer New York; 2000:39-77.
- 34. von Kodolitsch Y, Schwartz AG, Nienaber CA. Clinical prediction of acute aortic
- dissection. *Arch Intern Med*. 2000;160:2977-2982. doi:
- 10.1001/archinte.160.19.2977

- 35. Adriaans BP, Wildberger JE, Westenberg JJM, Lamb HJ, Schalla S. Predictive
- imaging for thoracic aortic dissection and rupture: moving beyond diameters. *Eur*
- *Radiol*. 2019;29:6396-6404. doi: 10.1007/s00330-019-06320-7
- 36. Heuts S, Adriaans BP, Rylski B, Mihl C, Bekkers S, Olsthoorn JR, Natour E,
- Bouman H, Berezowski M, Kosiorowska K, et al. Evaluating the diagnostic
- accuracy of maximal aortic diameter, length and volume for prediction of aortic
- dissection. *Heart*. 2020;106:892-897. doi: 10.1136/heartjnl-2019-316251
- 37. Wu J, Qiu J, Xie E, Jiang W, Zhao R, Qiu J, Zafar MA, Huang Y, Yu C. Predicting
- in-hospital rupture of type A aortic dissection using Random Forest. *J Thorac Dis*.
- 2019;11:4634-4646. doi: 10.21037/jtd.2019.10.82
- 38. Popejoy AB, Fullerton SM. Genomics is failing on diversity. *Nature*.
- 2016;538:161-164. doi: 10.1038/538161a
- 39. Ding Y, Hou K, Xu Z, Pimplaskar A, Petter E, Boulier K, Prive F, Vilhjalmsson BJ,
- Olde Loohuis LM, Pasaniuc B. Polygenic scoring accuracy varies across the
- genetic ancestry continuum. *Nature*. 2023;618:774-781. doi: 10.1038/s41586-
- 023-06079-4
- 40. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J,
- Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome
- association and population-based linkage analyses. *Am J Hum Genet*.
- 2007;81:559-575. doi: 10.1086/519795
- 41. Genomes Project C, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin
- RM, Handsaker RE, Kang HM, Marth GT, McVean GA. An integrated map of



- 10.1038/nature11632
- 42. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, Boehnke M,
- Abecasis GR, Willer CJ. LocusZoom: regional visualization of genome-wide
- association scan results. *Bioinformatics*. 2010;26:2336-2337. doi:
- 10.1093/bioinformatics/btq419
- 43. Lawrence M, Huber W, Pages H, Aboyoun P, Carlson M, Gentleman R, Morgan
- MT, Carey VJ. Software for computing and annotating genomic ranges. *PLoS*
- *Comput Biol*. 2013;9:e1003118. doi: 10.1371/journal.pcbi.1003118
- 44. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set
- analysis of GWAS data. *PLoS Comput Biol*. 2015;11:e1004219. doi:
- 10.1371/journal.pcbi.1004219
- 45. Consortium GT. The GTEx Consortium atlas of genetic regulatory effects across
- human tissues. *Science*. 2020;369:1318-1330. doi: 10.1126/science.aaz1776
- 46. Wang G, Sarkar A, Carbonetto P, Stephens M. A simple new approach to
- variable selection in regression, with application to genetic fine mapping. *J R Stat*
- *Soc Series B Stat Methodol*. 2020;82:1273-1300. doi: 10.1111/rssb.12388
- 47. Wallace C. A more accurate method for colocalisation analysis allowing for
- multiple causal variants. *PLoS Genet*. 2021;17:e1009440. doi:
- 10.1371/journal.pgen.1009440
- 48. Dewey FE, Gusarova V, O'Dushlaine C, Gottesman O, Trejos J, Hunt C, Van
- Hout CV, Habegger L, Buckler D, Lai KM, et al. Inactivating Variants in



- 1133. doi: 10.1056/NEJMoa1510926
- 49. Verma A, Damrauer SM, Naseer N, Weaver J, Kripke CM, Guare L, Sirugo G,
- Kember RL, Drivas TG, Dudek SM, et al. The Penn Medicine BioBank: Towards
- a Genomics-Enabled Learning Healthcare System to Accelerate Precision
- Medicine in a Diverse Population. *J Pers Med*. 2022;12. doi:
- 10.3390/jpm12121974
- 50. Loh P-R, Danecek P, Palamara PF, Fuchsberger C, A Reshef Y, K Finucane H,
- Schoenherr S, Forer L, McCarthy S, Abecasis GR, et al. Reference-based
- phasing using the Haplotype Reference Consortium panel. *Nature Genetics*.

2016;48:1443-1448. doi: 10.1038/ng.3679

- 51. Das S, Forer L, Schönherr S, Sidore C, Locke AE, Kwong A, Vrieze SI, Chew
- EY, Levy S, McGue M, et al. Next-generation genotype imputation service and
- methods. *Nature Genetics*. 2016;48:1284-1287. doi: 10.1038/ng.3656
- 52. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D.
- Principal components analysis corrects for stratification in genome-wide
- association studies. *Nature Genetics*. 2006;38:904-909. doi: 10.1038/ng1847
- 53. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J, Wang Q, Collins
- RL, Laricchia KM, Ganna A, Birnbaum DP, et al. The mutational constraint
- spectrum quantified from variation in 141,456 humans. *Nature*. 2020;581:434-
- 443. doi: 10.1038/s41586-020-2308-7
- 54. Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S,
- Musolf A, Li Q, Holzinger E, Karyadi D, et al. REVEL: An Ensemble Method for

- Predicting the Pathogenicity of Rare Missense Variants. *Am J Hum Genet*.
- 2016;99:877-885. doi: 10.1016/j.ajhg.2016.08.016
- 55. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde
- M, Lyon E, Spector E, et al. Standards and guidelines for the interpretation of
- sequence variants: a joint consensus recommendation of the American College
- of Medical Genetics and Genomics and the Association for Molecular Pathology.
- *Genet Med*. 2015;17:405-424. doi: 10.1038/gim.2015.30
- 56. All of Us Research Program Genomics I. Genomic data in the All of Us Research
- Program. *Nature*. 2024;627:340-346. doi: 10.1038/s41586-023-06957-x
- 57. Venner E, Patterson K, Kalra D, Wheeler MM, Chen YJ, Kalla SE, Yuan B,
- Karnes JH, Walker K, Smith JD, et al. The frequency of pathogenic variation in
- the All of Us cohort reveals ancestry-driven disparities. *Commun Biol*.
- 2024;7:174. doi: 10.1038/s42003-023-05708-y
- 58. Khan A, Turchin MC, Patki A, Srinivasasainagendra V, Shang N, Nadukuru R,
- Jones AC, Malolepsza E, Dikilitas O, Kullo IJ, et al. Genome-wide polygenic
- score to predict chronic kidney disease across ancestries. *Nat Med*.
- 2022;28:1412-1420. doi: 10.1038/s41591-022-01869-1
- 59. Marcot BG, Hanea AM. What is an optimal value of k in k-fold cross-validation in
- discrete Bayesian network analysis? *Computational Statistics*. 2021;36:2009-
- 2031. doi: 10.1007/s00180-020-00999-9
- 60. Kuhn MW, H. Tidymodels: a collection of packages for modeling and machine learning using tidyverse principles. 2020.

- 61. Wilimitis D, Walsh CG. Practical Considerations and Applied Examples of Cross-
- Validation for Model Development and Evaluation in Health Care: Tutorial. *JMIR*
- *AI*. 2023;2:e49023. doi: 10.2196/49023
- 62. Kruschke JK, Liddell TM. The Bayesian New Statistics: Hypothesis testing,
- estimation, meta-analysis, and power analysis from a Bayesian perspective.
- *Psychon Bull Rev*. 2018;25:178-206. doi: 10.3758/s13423-016-1221-4
- 63. Kruschke JK. Rejecting or Accepting Parameter Values in Bayesian Estimation.
- *Advances in Methods and Practices in Psychological Science*. 2018;1:270-280.
- doi: 10.1177/2515245918771304
- 64. Kuhn M. tidyposterior: Bayesian Analysis to Compare Models using Resampling Statistics. 2022.
- 65. Harrell F. Statistically Efficient Ways to Quantify Added Predictive Value of New Measurements. In: *Statistical Thinking*. 2018.
- 66. Harrell JFE. Regression Modeling Strategies : With Applications to Linear
- Models, Logistic and Ordinal Regression, and Survival Analysis. In: *Springer*
- *Series in Statistics,*. Cham: Springer International Publishing : Imprint: Springer,;
- 2015:1 online resource (XXV, 582 pages 157 illustrations, 553 illustrations in
- color.
- 67. Fronczek J, Polok K, de Lange DW, Jung C, Beil M, Rhodes A, Fjølner J, Górka
- J, Andersen FH, Artigas A, et al. Relationship between the Clinical Frailty Scale
- 806 and short-term mortality in patients□≥□80 years old acutely admitted to the ICU:
- a prospective cohort study. *Critical Care*. 2021;25:231. doi: 10.1186/s13054-021-
- 03632-3

- 68. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or
- more correlated receiver operating characteristic curves: a nonparametric
- approach. *Biometrics*. 1988;44:837-845.
- 69. Akashi M, Higashi T, Masuda S, Komori T, Furuse M. A coronary artery disease-
- associated gene product, JCAD/KIAA1462, is a novel component of endothelial
- cell-cell junctions. *Biochem Biophys Res Commun*. 2011;413:224-229. doi:
- 10.1016/j.bbrc.2011.08.073
- 70. Douglas G, Mehta V, Al Haj Zen A, Akoumianakis I, Goel A, Rashbrook VS,
- Trelfa L, Donovan L, Drydale E, Chuaiphichai S, et al. A key role for the novel
- coronary artery disease gene JCAD in atherosclerosis via shear stress
- mechanotransduction. *Cardiovasc Res*. 2020;116:1863-1874. doi:
- 10.1093/cvr/cvz263
- 71. Guo B, Greenwood PL, Cafe LM, Zhou G, Zhang W, Dalrymple BP.
- Transcriptome analysis of cattle muscle identifies potential markers for skeletal
- muscle growth rate and major cell types. *BMC Genomics*. 2015;16:177. doi:
- 10.1186/s12864-015-1403-x

## **Tables, Figures, and Figure Legends**

## **Table 1: Clinical characteristics of Penn Medicine Biobank individuals with and**

#### **without thoracic aortic dissection.**





41

**Figure 1: Genome-wide association study results. A)** Manhattan plot of multi-trait genome-wide association study-by-subtraction results subtracting AscAoD and DesAoD from TAAD. Each point represents a genetic variant. Genome-wide significant (*P*<5x10-  $8$ ) loci are represented by peaks of red points that associate with diameter-independent dissection. The X-axis represents genomic position by chromosome and the y-axis represents the strength of association by  $-log_{10}(P-value)$ . **B)** Candidate genes, grouped by chromosome, were assigned to each genome-wide significant (*P*<5x10-8) locus in the diameter-independent "dissection" (red) and compared to the previously published TAAD GWAS (blue), ascending aortic diameter GWAS (purple), and descending aortic diameter GWAS (green) with previously unreported candidate genes denoted by stars. The size of each point corresponds to the strength of the association represented by  $log_{10}(P\text{-value})$ .





# **Central Illustration: GWAS-by-subtraction, polygenic risk score creation, and association of different PRS with prevalent thoracic aortic dissection in the Penn Medicine Biobank.** Analytic approach to the GWAS-by-subtraction of diameterindependent dissection followed by polygenic risk score creation and multivariable logistic regression analysis of the Dissection-PRS, TAAD-PRS, and AscAoD-PRS among all individuals in the PMBB to determine respective association with prevalent thoracic aortic dissection, adjusting for age, sex, and the first five genetic principal components. AscAoD-PRS = Ascending aortic diameter polygenic risk score; CI = confidence interval; OR = Odds ratio; sd = standard deviation; TAAD-PRS = thoracic aortic aneurysm and dissection polygenic risk score; Dissection-PRS = thoracic aortic dissection polygenic risk score.

43



## **Figure 3: Association of Dissection-PRS with prevalent dissection in multivariable logistic regression analysis adjusting for different clinical risk factors.**

Multivariable logistic regression analysis of the effect of Dissection-PRS on prevalent dissection adjusting for clinical risk factors, measured AscAoD, or clinical risk factors and measured AscAoD. Each logistic regression analysis was also adjusted for age, sex, and the first five genetic principal components. AscAoD = Ascending aortic diameter measured by TTE or CT; CI = confidence interval;  $OR = Odds$  ratio; sd = standard deviation; Dissection-PRS = thoracic aortic dissection polygenic risk score.



**Figure 4: Logistic regression model receiver operator characteristic curve (ROC) and area under the ROC curve to predict thoracic aortic dissection.** (A) Receiver operator characteristic curves for each of the primary models including Age + Sex, Age + Sex + CRF, Age + Sex + CRF + Dissection-PRS, Age + Sex + CRF + AscAoD, and Age + Sex + CRF + AscAoD + Dissection-PRS. (B) Corresponding area under the ROC curves with error bars demonstrating 95% confidence intervals for models utilized among all individuals. AscAoD = ascending thoracic aortic diameter;  $AUROC = area$ under the receiver operator characteristic curve;  $CI = 95\%$  confidence interval;  $CRF =$ Clinical Risk Factors; Dissection-PRS = thoracic aortic dissection polygenic risk score.